Latest AtaiBeckley News & Updates

See the latest news and media coverage for AtaiBeckley. We track all announcements, press releases, and industry mentions in real time, all in one place.

AtaiBeckley

Mental health biotech company

ataibeckley.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about AtaiBeckley

In short: AtaiBeckley was acquired by Eli Lilly for $2.8 billion, significantly expanding Lilly's pipeline for treatment-resistant depression.

Company announcements

July 16 AtaiBeckley

AtaiBeckley acquired by Lilly for $2.8 billion

The deal includes potential milestone payments and expands Lilly's neuroscience pipeline for treatment-resistant depression.

July 6 AtaiBeckley

AtaiBeckley completes enrollment in VLS-01 Phase 2b TRD trial

Topline data due Q4 2026; intends to start Phase 3 for major depressive disorder.

April 22 AtaiBeckley

AtaiBeckley announces additional Phase 2a results for EMP-01

The trial demonstrated clinically meaningful reductions in SAD symptoms and high responder rates with no serious adverse events.

April 8 AtaiBeckley

AtaiBeckley's BPL-003 shows rapid antidepressant response in Phase 2a trial

The drug achieved 66.7% response rate by Day 2 and durable effects through Week 12, with FDA Breakthrough Therapy designation and Phase 3 initiation on track for Q2 2026.

Media coverage

August 16 Business Wire

Dominion Energy Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dominion Energy, Inc. - D

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC...

July 22 MSN

How much upside is left in AtaiBeckley Inc (ATAI)? Wall Street analysts think 33.33%

AtaiBeckley Inc (ATAI) closed the last trading session at $7.14, gaining 74% over the past four weeks, but there could be ...

July 16 Las Vegas Sun

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether AtaiBeckley Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of AtaiBeckley Inc. (NASDAQ: ATAI) to Eli Lilly and Company for $6.75 per...

July 15 Reuters

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic drug developer as soon as...

Never miss news about AtaiBeckley

Track AtaiBeckley and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AtaiBeckley competitors & trending companies

Browse news for competitors to AtaiBeckley and other trending companies.